This prospective study describes chemotherapy-induced nausea and vomiting (CINV) in children (4-18 years) receiving their first hematopoietic stem cell transplant. Emetic episodes, nausea severity (assessed using a validated, self-report nausea severity assessment tool) and antiemetic administration were documented from the start of conditioning until 24 h after the last conditioning agent was administered (acute) and for a further 7 days (delayed). Relationships between CINV control and parenteral nutrition (PN) use and acute gut GvHD (aGvHD) were explored. Fifty-nine children (4.6-17.4 years) were evaluable. Complete chemotherapy-induced vomiting (CIV; acute: 24%; delayed 22%) and chemotherapy-induced nausea (CIN; acute 7%; delayed 12%) control rates were low. Few children experienced complete CINV control (no vomiting/retching and no nausea) during the acute (5%) or delayed phases (12%). Children experiencing complete acute or delayed CIN control or complete delayed CIV control were more likely to have received: a lower proportion of their total energy requirement as PN at the end of the delayed phase (P o 0.036) and PN for a shorter time (P o0.044). Low patient numbers did not permit evaluation of the association between gut aGvHD and CINV control. Effective and safe interventions aimed at improving CINV control in children are required.
INTRODUCTION
Despite recent advances in the use of modern antiemetic agents, nausea and vomiting continue to be among the most common and distressing side effects associated with chemotherapy. Control of chemotherapy-induced nausea and vomiting (CINV) during hematopoietic stem cell transplant (HSCT) conditioning is recognized as particularly difficult since multiple, often highly emetogenic, chemotherapy agents are administered over several consecutive days to patients who may have experienced CINV during past chemotherapy cycles. 1, 2 It is well-recognized that CINV impairs quality of life. Through its effect on enteral intake, CINV in the HSCT population may also increase mucositis severity, increase the risk of hepatobiliary toxicity and increase gut acute GvHD (aGvHD) severity. [3] [4] [5] [6] We have previously shown that complete chemotherapy-induced vomiting (CIV) control in pediatric HSCT patients is seldom achieved. 7 Nausea control in pediatric HSCT patients has never been evaluated using a validated tool.
The primary objective of this study was to describe the prevalence of acute and delayed phase CINV using the Pediatric Nausea Assessment Tool (PeNAT), 8 a validated, child self-report nausea severity assessment tool, in children aged 4-18 years receiving HSCT conditioning. We also explored the relationship between CINV control and the use of parenteral nutrition (PN) and, in children receiving allogeneic HSCT, the development of aGvHD.
SUBJECTS AND METHODS
This prospective, observational study was approved by the SickKids' Research Ethics Board. Patients or their guardian provided informed consent to participate. When consent to participate was provided by a guardian, patients who were able to do so also provided assent.
Patients
Participants were: 4-18 years of age; English-speaking; without cognitive or physical impairments that would preclude the use of the PeNAT 8 and were planned to receive their first allogeneic or autologous HSCT at SickKids for an indication other than immunodeficiency. Children participated in this study once only.
Definitions
Vomiting was defined as the expulsion of any stomach contents through the mouth. Retching was defined as an attempt to vomit that was not productive of stomach contents. An emetic episode was defined as a vomit or a retch that was separated from another vomit or retch by at least 1 min. Chemotherapy emetogenicity was classified using a pediatric guideline. 9 The acute phase was defined as beginning with the first dose of HSCT conditioning and ending 24 h after the last dose of HSCT conditioning including TBI. Thus, the duration of the acute phase for each patient depended on the conditioning regimen. The delayed phase was defined as starting immediately after the acute phase and ended 7 days (168 h) later.
Data collection
The study period began immediately with the administration of the first dose of HSCT conditioning and continued until transfer to another institution or death to a maximum of 100 days post HSCT. Data collected for each patient included: age; sex; weight; height; indication for HSCT; type of HSCT; conditioning regimen (agents, dose and time of administration); antiemetic agents administered; goal energy requirements; start date and end date of PN and, for patients undergoing allogeneic HSCT, maximal grade and stage of aGvHD.
Nausea and vomiting assessment
After instruction, the patient or their guardian recorded emetic episodes and nausea severity in diaries provided for this purpose. Children self-reported nausea severity using the PeNAT 8 twice daily on rising in the morning and at bedtime at minimum, as well as at any other time the child felt nauseated or their guardian believed that the child may feel nauseated. The PeNAT consists of three elements: determination of the words or expressions for nausea used within each child's family; a script to center the child on the subjective symptom of nausea and that explains the PeNAT, and a nausea severity scale that incorporates four faces. PeNAT scores correspond to no nausea (1), mild nausea (2), moderate nausea (3) and severe nausea (4). The PeNAT was first administered to each child by a co-investigator who then taught the child's caregiver to administer the PeNAT. Although a guardian or a health-care provider could assist the patient to complete nausea severity assessments, they merely transcribed the information provided by the child. They did not make a proxy assessment of the severity of the child's nausea. Patients or their guardian were contacted in person approximately three times per week during the acute and delayed phases of CINV monitoring to promote adherence to study procedures and collect completed diaries. If a child's completed diary pages were not available, the number of times the child vomited was abstracted from the health record.
PN use
The proportion of each patient's goal energy requirements (basal metabolic rate × 1.5) provided by PN was calculated on the first day of HSCT conditioning and on the last day of the delayed phase. If a patient was receiving PN when admitted for HSCT, the start date was considered to be the first day of conditioning. If a patient was transferred to another center prior to termination of PN, the end date of PN was considered to be the date of discharge unless there was correspondence in the health record regarding the actual date of PN termination. Patients who died while receiving PN were not included in this analysis.
aGvHD assessment
Maximal aGvHD grade and stage experienced by each patient was assessed prospectively using the modified Glucksberg 10,11 criteria and verified by a physician co-investigator independently. In cases of discrepancy between the maximal grade/stage charted and the co-investigator's opinion, a second physician co-investigator reviewed the case and the assessment was made by consensus.
Analysis
A sample size of convenience of 60 patients was chosen for this study. The primary study end point was complete control of CINV in the acute and delayed phases of conditioning, defined as no emetic episodes and no nausea (maximum PeNAT score of 1). The proportion of children achieving complete, partial and failed CIV, chemotherapy-induced nausea (CIN) and CINV control (Table 1) in the acute and delayed phases was calculated. CIN control was calculated for the acute and delayed phases if PeNAT scores were missing on no more than 1 day within the acute phase or on no more than 2 days within the delayed phase. The health record was not used to extrapolate a PeNAT score. The proportion of days within the acute and delayed phases that were free of CIV and CIN was also calculated.
The relationships between complete CINV control and PN use (proportion of goal energy requirements provided by PN at the end of the delayed phase and total number of days of PN) and presence of aGvHD were explored using Fisher's exact test, χ 2 -test or Kruskal-Wallis test. Statistical analysis was performed using SAS Enterprise Guide (6.100.0.2870; SAS Institute Inc., Cary, NC, USA).
RESULTS
Of the 214 consecutive patients admitted for HSCT at SickKids between January 2012 and February 2015 and screened for study eligibility, 115 met the eligibility criteria and 100 were invited to participate. Sixty children entered the study. One patient found completion of the diaries to be burdensome and withdrew. This patient did not contribute to the analysis. Two patients died before day +100; one was receiving PN at the time of death. The number of patients included in the analyses are presented in Figure 1 .
Characteristics of patients, conditioning regimens and HSCT are summarized in Table 2 . Most (83%) children received HSCT conditioning that contained highly emetogenic chemotherapy; cyclophosphamide was the most commonly administered agent (68%). During the acute phase, all patients received CINV prophylaxis. Most received ondansetron/granisetron plus dexamethasone, alone (63%) or in combination with other antiemetic agents (nabilone (12%), lorazepam (2%), nabilone plus dimenhydrinate (2%)). Others received ondansetron/granisetron either alone (12%) or in combination with nabilone (8%). One child received palonosetron plus dexamethasone. The majority of children (80%) received dexamethasone. The mean doses of ondansetron, granisetron and dexamethasone administered during the acute phase are presented in Table 3 . All children continued to receive antiemetic medication during the delayed phase. The median duration of scheduled (not as needed) antiemetic medication administration during the delayed phase was 5 days (interquartile range: 2-7 days).
Acute and delayed phase CIN, CIV and CINV The diary completion rate, defined as the proportion of diary pages that were completed and returned, was 94% and 90% in the acute and delayed phases, respectively. The mean length of the acute phase was 147 h (range: 50.3-240.2 h); the duration of the delayed phase was 7 days (168 h) for all children.
Vomiting frequency was abstracted from the health record during the acute phase for 7 children (22 days) and the delayed phase for 8 children (30 days). Evaluation of acute CIN was not possible in four children since insufficient PeNAT scores were available. Thus, acute CIV was evaluable in 59 children, while acute CIN and CINV control were evaluable in 55 children. During the delayed phase, vomiting records were not available for one child and PeNAT scores from 10 children were available on fewer than 5 days. As a result, delayed CIV was evaluable in 58 children; delayed CIN and CINV control were evaluable in 49 children ( Figure 1 ). Reported levels of acute and delayed phase CIN, CIV and CINV control for moderately and highly emetogenic HSCT conditioning regimens are summarized in Table 4 . Complete acute CIV and CIN control was achieved in 24% (14/59) and 7% (4/55) of children, respectively. Few children (3/55; 5%) experienced complete acute CINV control. Of note, most children (78%; 46/59) received antiemetic agents at least once on an as-needed basis during the acute phase. Complete delayed CIV control was achieved in 22% (13/58) of children, whereas complete delayed CIN control was achieved only in 12% (6/49). The proportion of children who experienced complete delayed CINV control was similarly low (6/49; 12%). Again, most children (75%; 44/59) received antiemetic agents on an as-needed basis during the delayed phase.
The number of emetic episodes per day during the acute phase ranged from 0 to 12 and, in the delayed phase, from 0 to 15. On each day of the acute and delayed phases, the maximum PeNAT scores ranged from 1 to 4 and from 1 to 3, respectively. On average, patients were free of CIV on 70 ± 28% (median: 75%) and 59 ± 31% (median: 57%) of days during the acute and delayed phases, respectively. During the acute and delayed phases, the mean proportions of CIN-free days were 38 ± 32% (median: 35%) and 37 ± 37% (median: 14%).
No complications that may have been associated with vomiting or nausea were observed in any patient during the acute phase. During the delayed phase, four patients developed complications that may have caused vomiting or nausea: pancreatitis (one patient), Clostridium difficile diarrhea (one patient) and upper gastrointestinal bleeding (two patients). Cases were identified on the second day (pancreatitis, and upper gastrointestinal bleeding) or third day of the delayed phase (C. difficile diarrhea). Delayed phase CIV, CIN and CINV were not evaluable in one of these patients, and CIN and CINV were not available in another. Of the remaining patients, delayed phase CIV was partially controlled in Chemotherapy-induced nausea and vomiting in children J Flank et al two and uncontrolled in a third; and delayed phase CIN and CINV were partially controlled or uncontrolled each in one patient. Cyclophosphamide was the most common HSCT conditioning agent administered in our cohort. Of the 40 children who received HSCT regimens containing cyclophosphamide, acute CIV was evaluable in 40 and acute CINV was evaluable in 36. Of these, eight children (8/40; 20%) experienced complete acute CIV control, while two (2/36; 6%) experienced complete acute CIN and complete acute CINV control. Delayed CIV, CIN and CINV were evaluable in 40, 35 and 35 children, respectively. Complete control of delayed CIV, CIN and CINV were again low (complete delayed CIV control: 23%; complete delayed CIN control: 14%; complete delayed CINV control: 14%).
CINV control and PN Two children were receiving PN before the initiation of HSCT conditioning and 40 (69%) were receiving PN at the end of the delayed phase. PN was initiated in most children (83%; 49/59) during the time period from the start of HSCT conditioning through the first 100 days following HSCT. CIV and CIV control were associated with reduced reliance on PN. Compared to children who vomited or who had nausea, children who experienced complete delayed phase CIV control or complete CIN control in either the acute or delayed phases received a lower proportion of their energy requirements as PN at the end of the delayed phase (P o0.036; Table 5 ). Furthermore, children who did not vomit or did not experience nausea in either the acute or delayed phases received PN for a shorter period of time than those who vomited or experienced nausea. (P o0.044; Table 5 ).
CINV control and aGvHD Of the 36 children in our cohort who underwent allogeneic HSCT, 11 developed aGvHD (grade 1:1; grade 2:5; and grade 3:5). Three children had acute gut GvHD (stage 2:2; stage 1:1). Patient numbers were insufficient to evaluate differences in gut aGvHD among children based on CINV control.
DISCUSSION
Using a validated pediatric nausea severity assessment tool, we have shown that control of acute and delayed CINV is exceedingly poor in children receiving myeloablative chemotherapy for HSCT conditioning despite the administration of modern CINV prophylaxis. Indeed, CINV is an almost universal experience.
Little high-quality evidence describing interventions aimed at improving CIV control in children receiving HSCT conditioning exists. Differences in study methods, patient populations, conditioning regimens, CINV prophylaxis provided and definitions of CINV end points make comparisons challenging. However, two prospective studies are noteworthy. First, Orchard et al. 12 conducted a double-blind, randomized trial to compare ondansetron vs granisetron monotherapy in patients receiving HSCT. This trial included 51 children and 136 adults. Although the complete acute CIV control rate was not reported for the acute phase as a whole, patients receiving granisetron and ondansetron experienced no emesis on 63% and 61% of patient days, respectively. Pediatric data were not reported separately, but no differences were observed between study arms based on age.
Second, in an open, prospective study, Hewitt et al. 13 evaluated the number of emetic episodes in 15 children receiving ondansetron during HSCT conditioning with cyclophosphamide with or without TBI. Nine children (9/15; 60%) experienced no vomiting or retching on the days that cyclophosphamide was administered and six of the 11 children who went on to receive TBI experienced no vomiting or retching during that period. Again, the complete CIV control rate for the entire acute phase was not reported.
Most patients in our cohort received dexamethasone in addition to a 5-HT3 antagonist for CINV prophylaxis. There are no published evaluations of this antiemetic combination in children undergoing HSCT. However, Frakes et al.
14 reported complete acute CIV control 53% in adults (19/36) receiving HSCT conditioning with cyclophosphamide, thiotepa and carboplatin together with CINV prophylaxis with granisetron, dexamethasone and prochloperazine. During the study period, our institutional Chemotherapy-induced nausea and vomiting in children J Flank et al CINV prophylaxis guideline recommended a dexamethasone dose of 6 mg/m 2 per dose given every 6 h for children o 12 years of age and 20 mg once daily in older children. The mean dexamethasone doses administered to patients in our cohort were in compliance with our guideline though the frequency of administration was more variable.
The present study is the first pediatric study to evaluate nausea control using a validated tool during HSCT. 8 Both CIV and CIN control rates are disturbingly low in our cohort. CIV control may have been improved with the addition of aprepitant during the acute phase. However, all children who participated in this study received chemotherapy known or suspected to interact with aprepitant. A NK-1 antagonist that does not influence the CYP3A4 pathway merits investigation for use in these cases. The low rates of complete CIN control are perhaps not surprising, given that currently recommended antiemetic prophylaxis is aimed at CIV, not CIN, control. Interventions that target pathways other than 5-HT3 and NK-1 are likely required to improve CIN control. 15 Olanzapine 16 and gabapentin 17 have shown promise in improving CIN control in adults and merit prospective evaluation in children.
Although this was an exploratory aim, we are the first to report a link between CINV control and PN use. CIN control may be more important than CIV control in this regard. By influencing both the extent and duration of PN use in HSCT, acute and delayed CINV may affect the risks of hepatobiliary toxicity and gut aGvHD. 4, 5 Minimization of eating disruptions also is an important determinant of quality of life following transplant, at least in adolescents, 18 and maintenance of enteral intake may reduce mucositis severity. 6 Finally, improvement in complete CINV control may result in cost savings through reduction in PN use.
Our study may be limited by the possibility of selection bias. It is possible that past experience with CINV may have encouraged or discouraged patient participation. Patients who received HSCT conditioning that was either highly and moderately emetogenic were included in this study. Since CINV control was poor in both groups, this diversity does not impact the significance of our findings. Similarly, patients may have vomited or experienced nausea due to medication other than HSCT conditioning agents or to concurrent conditions. In addition, this study may have been limited by the reliance on the patients and their parents to complete the PeNAT as per the investigator's instructions. However, this was largely addressed by frequent dialogue with the patients and their parents regarding study procedures.
In conclusion, control of acute and delayed CIV in children receiving HSCT conditioning remains poor and CIN control is even worse. Optimization of CINV control during and shortly following HSCT conditioning administration will improve the quality of life of children during conditioning. Even more importantly, CINV control may prevent or mitigate significant transplant-related morbidity. Routine monitoring of nausea severity may facilitate timely clinical decision-making with respect to CINV prophylaxis or treatment. However, to safely, effectively and significantly improve CINV control in children receiving HSCT and to delineate the clinical ramifications of CINV, specific pediatric trials evaluating the efficacy of agents with both antiemetic and antinauseant activity are required.
